June 11th, 2019

Allgenesis In the News: Our CEO Dr. Cherukury was interviewed by Macular Degeneration Foundation at the 2019 ARVO Conference (Association for Research in Vision and Ophthalmology). Dr. Cherukury discussed the three projects Allgenesis presented at 2019 ARVO Conference, but focused on AG-73305, a bi-specific protein molecule that has potential to become a leading treatment option for retinal diseases. Please see the link below to the video below:

For video on Macular Degeneration Foundation, please click here.

About Allgenesis

Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is in the CMC stage of the development with IND filing before 1Q2021. AG-86893, a drug for the treatment of Pterygium or better-known as “surfer’s eye”, is in Phase 2a clinical trial in Australia with first-patient-enrolled in 4Q2018.

About Macular Degeneration Foundation, Inc.

Macular Degeneration Foundation, Inc. is a 501c3 tax-exempt charitable foundation. It was founded in 1989 by Edmund J. Alex, a Silicon Valley business man who developed age-related macular degeneration in his mid 70’s. Until his death in 2009 at the age of 94, Ed dedicated his life to raising awareness of a disease that was practically unknown. He began raising money for research and published a newsletter called the MAGNIFIER designed to inform and assist others with low vision to cope with the disease.

About AG-73305

AG-73305 is the first-in-class molecule specifically designed for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is a single fusion protein that simultaneously binds to VEGF and integrins with high potency and specificity. During the discovery stage, AG-73305 demonstrated promising efficacy in protecting the blood-retina-barrier in a rabbit POC model and in a laser-induced CNV monkey model. AG-73305 has desirable ocular pharmacokinetics and was well-tolerated in monkeys after intravitreal injection.